



# Kilitch Drugs (India) Ltd.

21<sup>st</sup> January, 2025

To,  
The Manager - Corporate Relationship Dept.  
BSE Limited  
P. J. Towers, Dalal Street  
Fort, Mumbai - 400 001

To,  
The Manager - Corporate Compliance  
National Stock Exchange of India Ltd  
Exchange Plaza, Plot No.C-1, G Block,  
BKC, Bandra (E), Mumbai 400 051

**Scrip Code: BSE - 524500**

**Scrip Code: NSE - KILITCH**

## **Sub: Disclosure Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015**

Dear Sir,

Pursuant to provisions of regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby would like to inform you that the Company has made additional investment of USD 2,00,000 to acquire equity shares of Kilitch Estro Biotech PLC, foreign subsidiary of the Company to meet working capital requirement of the Company.

The details of the Kilitch Estro Biotech PLC, foreign subsidiary of the company, equity shares of which are being acquired are mentioned herein below;

Particulars	Details	
Name of the target entity	Kilitch Estro Biotech PLC	
Turnover (Rs.)	<b>31<sup>st</sup> March, 2024</b>	<b>21<sup>st</sup> March, 2023</b>
	22,72,04,731	22,22,10,801
Whether related party transaction	Yes	
Whether Promoter / Promoter Group/ Group Companies have any interest?	Mr. Mukund Mehta, Promoter and Mr. Bhavin Mehta, Promoter Group of the Company are directors of Kilitch Estro Biotech PLC	
Whether the transaction is on arm's length basis ?	Yes	
Industry to which the entity being acquired belongs	Pharmaceutical	
Object and effects of acquisition	To enhance investment of Kilitch Drugs (India) limited for long term return of investment and to meet fund requirement of the subsidiary	
Governmental or Regulatory approvals required for the acquisition	No prior approval is required.	





## Kilitch Drugs (India) Ltd.

Indicative time period for completion of the acquisition	3 - 6 months.
Nature of Consideration	Cash Consideration
Cost of Acquisition	Rs. 1,73,22,000
Number of Shares acquired	25,092 shares
Brief Background of the Company	Kilitch Estro Biotech PLC is engaged in manufacturing of Pharmaceutical Products incorporated in September, 2015 in Ethiopia, commenced its production in January, 2022
Pre and Post percentage of holding	Percentage of holding Pre – issue is 67%. Percentage of holding Post – issue will be 78.09%

We request you to kindly take the same on record and acknowledge the receipt.

Thanking you,

Yours Faithfully,

For **Kilitch Drugs (India) Limited**

**Mukund Mehta**  
**Managing Director**

